Literature DB >> 9558161

Mannan binding lectin in rheumatoid arthritis. A longitudinal study.

N A Graudal1, C Homann, H O Madsen, A Svejgaard, A G Jurik, H K Graudal, P Garred.   

Abstract

OBJECTIVE: Low serum levels of mannan binding lectin (MBL) are associated with increased risk of recurrent infections. We determined whether there was an association between serum MBL levels and the course and prognosis of rheumatoid arthritis (RA).
METHODS: MBL was analyzed in sera from 99 patients with RA who were included in a longterm prospective study.
RESULTS: Compared with controls, a high fraction of patients lacked detectable MBL in serum (11 vs 3%; p = 0.025). Comparing patients with MBL serum levels above and below the median revealed that those with levels below the median were younger at onset of RA (p = 0.043) and had higher erythrocyte sedimentation rate (p = 0.006), joint swelling score (p = 0.019), limitation of joint motion score (p = 0.027), and annual increase in radiographic destruction score (p = 0.053).
CONCLUSION: MBL insufficiency may be a contributing pathogenetic factor in RA.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9558161

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  21 in total

Review 1.  Complement genetics, deficiencies, and disease associations.

Authors:  Karine R Mayilyan
Journal:  Protein Cell       Date:  2012-07-10       Impact factor: 14.870

2.  Polymorphisms of the mannose binding lectin gene in patients with Sjögren's syndrome.

Authors:  Z Y Wang; A Morinobu; S Kanagawa; S Kumagai
Journal:  Ann Rheum Dis       Date:  2001-05       Impact factor: 19.103

3.  Recombinant form of human wild type mannan-binding lectin (MBL/A) but not its structural variant (MBL/C) promotes phagocytosis of zymosan by activating complement.

Authors:  Rema Rajagopalan; Takazvida Nyaundi; Veena P Salvi; Nenoo Rawal
Journal:  Mol Immunol       Date:  2010-06-25       Impact factor: 4.407

4.  Association of mannose-binding lectin gene heterogeneity with severity of lung disease and survival in cystic fibrosis.

Authors:  P Garred; T Pressler; H O Madsen; B Frederiksen; A Svejgaard; N Høiby; M Schwartz; C Koch
Journal:  J Clin Invest       Date:  1999-08       Impact factor: 14.808

Review 5.  Protective molecules--C-reactive protein (CRP), serum amyloid P (SAP), pentraxin3 (PTX3), mannose-binding lectin (MBL), and apolipoprotein A1 (Apo A1), and their autoantibodies: prevalence and clinical significance in autoimmunity.

Authors:  Martine Szyper Kravitz; Milena Pitashny; Yehuda Shoenfeld
Journal:  J Clin Immunol       Date:  2005-11       Impact factor: 8.317

6.  Mannose-binding lectin 2 gene haplotype analysis in Korean patients with ankylosing spondylitis.

Authors:  Churl Hyun Im; Jinhyun Kim; Yun Jong Lee; Eun Young Lee; Eun Bong Lee; Kyung Sook Park; Yeong Wook Song
Journal:  Rheumatol Int       Date:  2011-05-05       Impact factor: 2.631

Review 7.  Nitrosothiols in the immune system: signaling and protection.

Authors:  Pablo Hernansanz-Agustín; Alicia Izquierdo-Álvarez; Almudena García-Ortiz; Sales Ibiza; Juan M Serrador; Antonio Martínez-Ruiz
Journal:  Antioxid Redox Signal       Date:  2012-08-17       Impact factor: 8.401

8.  Reactive arthritis and serum levels of mannose binding lectin -- lack of association.

Authors:  H Locht; M Christiansen; I Laursen
Journal:  Clin Exp Immunol       Date:  2003-01       Impact factor: 4.330

9.  Mannose-binding lectin gene polymorphic variants predispose to the development of bronchopulmonary complications but have no influence on other clinical and laboratory symptoms or signs of common variable immunodeficiency.

Authors:  J Litzman; T Freiberger; B Grimbacher; B Gathmann; U Salzer; T Pavlík; J Vlcek; V Postránecká; Z Trávnícková; V Thon
Journal:  Clin Exp Immunol       Date:  2008-07-11       Impact factor: 4.330

10.  Smoking and polymorphisms of genes encoding mannose-binding lectin and surfactant protein-D in patients with rheumatoid arthritis.

Authors:  Malthe Kristiansen; Morten Frisch; Hans Ole Madsen; Peter Garred; Søren Jacobsen
Journal:  Rheumatol Int       Date:  2013-11-22       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.